Cargando…
Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
BACKGROUND: The purpose of this study was to compare the efficacy and safety of utidelone plus capecitabine for advanced first-line versus second-line or above therapy in metastatic breast cancer patients who had previously received anthracycline and taxane. At the same time, we compared the efficac...
Autores principales: | Bi, Pingping, Wang, Xi, Liu, Rui, Li, Xiuqin, Wei, Shanrong, Zhao, Jiawen, Tan, Xin, Zhang, Fan, Mao, Qing, Zhang, Ying, Tang, Baoyan, Xun, Xueqiong, Guo, Rong, Zheng, Kai, Zhou, Shaoqiang, Tang, Shicong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665706/ https://www.ncbi.nlm.nih.gov/pubmed/38026829 http://dx.doi.org/10.1016/j.sopen.2023.10.008 |
Ejemplares similares
-
Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016) -
Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial
por: Xu, Junnan, et al.
Publicado: (2020) -
Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway
por: Li, Fuli, et al.
Publicado: (2021) -
Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012) -
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)